Digital ILC Day Three Highlights: Late breakers, COVID and more – Ep 23

Day Three into EASL Digital ILC 2020
()

 
Browse Our NASH and COVID-19 Coverage
 

SurfingNASH’s Digital ILC coverage ends with three late-breaking drug presentations, a discussion of EASL’s COVID efforts, and insights on patient management.

Professor Joern Schattenberg joins the Surfers to discuss the last day of Digital ILC. Donna Cryer and Roger Green praise the work EASL has done pulling together data and analysis on how #liverdisease affects #COVID19 treatment decisions and outcomes, while Louise Campbell discusses research-in-process and Stephen, Peter Traber and Prof. Dr. Jörn M. Schattenberg discuss two exciting drugs in development and combination therapy that teaches us lessons about underlying liver dysfunction. In the end, Donna discusses GLI’s “Beyond the Biopsy” initiative. This episode is knowledge-dense but entertaining… and totally a “can’t miss” episode!


How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Advance Notification

We send out emails to notify our followers before we post on social media, and often it's before your podcast app is updated!